Financial analysis of Johnson & Johnson 2006 results (NYSE:JNJ)
Posted by: dk in US Stock
founded: 1886, NYSE code: JNJ, homepage: www.investor.jnj.com
Overview
Johnson & Johnson is a great example of a traditional, well established top business performer of the health care industry. Its main business is production and sale of large variety of health and hygienic products distributed to the worldwide markets under such household names as Band-Aid, Clean & Clear, Sudafed, Stayfree, Listerine, Nicorette, Johnson&Johnson and other.
In 2006, Johnson & Johnson gave work to about 122,000 employees through its 250 subsidiaries residing in 57 countries such as Ireland, France, Australia, Pakistan, Phillipines, Mexico and China just to name a few. In 2006, the US market contributed to the the overal company result by making 56% of total sales and the International subsidiaries were responsible for the remaining 44%were made on the US and remaining 44% of sales.
From the market segment prospective, the best Johnson & Johnson performer by net trade numbers in 2006 were products falling within the Pharmaceuticals category (44% of the total net trades; eg. REMICADE, ACIPHEX) followed by Medical Devices (38%; eg. Acuvue contact lenses) and Consumer (18%; eg. Johnson’s Baby line, Band-Aid) items.
Analysis of December 2006 financial results:
- Market Cap: Depending on the daily prices of the company’s stock the total market capitalization is around US$195 billion over 2.96 billion of issued shares
- Shareholders’ Equity: US$40.2 billion making the stock’s book value approx. US$13.60 per share (4.5% growth on FY 2005)
- Earnings per share: US$3.73 making the average EPS growth in last 5 years about 16.5%
- Return on Equity: 27.5%, averaging around 25.9%pa in last 5 years
- Balance Sheet: Working capital of US$3.8 billion (ie. US$1.29 per share) versus long term debt of US$2 billion

Sharemaket’s valuation:
Average JNJ’s Price to Earnings ratio of 28 suggests the share price around US$104.- (US$3.73 EPS x 28 P/E)
GROWTH STOCK:
- Conservative forecast of average EPS growth in next 10 years: 13%
- Share price in 10 years time: about US$355 (EPS in year 10 based on forecasted yearly EPS growth times average P/E)
- Total shareholders return in 10 years time: US$386 (share price of US$355 plus US$31 of the 10 years worth of dividends if the current payout ratio of about 40% persists)
- Rate of Return in next 10 years based on the beginning of January 2008 stock price of US$67.85 per share: 18.9%pa
Pros and cons:
+++ Established world market leader on the field of healthcare products
+++ Constantly showing excellent levels of ROE and continuous earnings growth year after year
+++ Very strong balance sheet where, if necessary, the entire long term debt could be comfortably paid off using only a portion of the current cash in bank alone
+++ Reluctant to issuing new shares hence constantly increasing the value for its current and long term stock holders
— Internal stock ownership within the top management seems to be somehow low
Don’t to miss any of the upcoming articles on this website and subscribe to our RSS Feed NOW!



Entries (RSS)